Cargando…

Investigator experiences with financial conflicts of interest in clinical trials

BACKGROUND: Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce their objectivity. We obtained information from investigators about adherence to practices that minimize the introduction of such bias in their clinical trials experience. METHODS: Em...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochon, Paula A, Sekeres, Melanie, Hoey, John, Lexchin, Joel, Ferris, Lorraine E, Moher, David, Wu, Wei, Kalkar, Sunila R, Van Laethem, Marleen, Gruneir, Andrea, Gold, Jennifer, Maskalyk, James, Streiner, David L, Taback, Nathan, Chan, An-Wen
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031202/
https://www.ncbi.nlm.nih.gov/pubmed/21226951
http://dx.doi.org/10.1186/1745-6215-12-9
_version_ 1782197324825493504
author Rochon, Paula A
Sekeres, Melanie
Hoey, John
Lexchin, Joel
Ferris, Lorraine E
Moher, David
Wu, Wei
Kalkar, Sunila R
Van Laethem, Marleen
Gruneir, Andrea
Gold, Jennifer
Maskalyk, James
Streiner, David L
Taback, Nathan
Chan, An-Wen
author_facet Rochon, Paula A
Sekeres, Melanie
Hoey, John
Lexchin, Joel
Ferris, Lorraine E
Moher, David
Wu, Wei
Kalkar, Sunila R
Van Laethem, Marleen
Gruneir, Andrea
Gold, Jennifer
Maskalyk, James
Streiner, David L
Taback, Nathan
Chan, An-Wen
author_sort Rochon, Paula A
collection PubMed
description BACKGROUND: Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce their objectivity. We obtained information from investigators about adherence to practices that minimize the introduction of such bias in their clinical trials experience. METHODS: Email survey of clinical trial investigators from Canadian sites to learn about adherence to practices that help maintain research independence across all stages of trial preparation, conduct, and dissemination. The main outcome was the proportion of investigators that reported full adherence to preferred trial practices for all of their trials conducted from 2001-2006, stratified by funding source. RESULTS: 844 investigators responded (76%) and 732 (66%) provided useful information. Full adherence to preferred clinical trial practices was highest for institutional review of signed contracts and budgets (82% and 75% of investigators respectively). Lower rates of full adherence were reported for the other two practices in the trial preparation stage (avoidance of confidentiality clauses, 12%; trial registration after 2005, 39%). Lower rates of full adherence were reported for 7 practices in the trial conduct (35% to 43%) and dissemination (53% to 64%) stages, particularly in industry funded trials. 269 investigators personally experienced (n = 85) or witnessed (n = 236) a fCOI; over 70% of these situations related to industry trials. CONCLUSION: Full adherence to practices designed to promote the objectivity of research varied across trial stages and was low overall, particularly for industry funded trials.
format Text
id pubmed-3031202
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30312022011-02-01 Investigator experiences with financial conflicts of interest in clinical trials Rochon, Paula A Sekeres, Melanie Hoey, John Lexchin, Joel Ferris, Lorraine E Moher, David Wu, Wei Kalkar, Sunila R Van Laethem, Marleen Gruneir, Andrea Gold, Jennifer Maskalyk, James Streiner, David L Taback, Nathan Chan, An-Wen Trials Research BACKGROUND: Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce their objectivity. We obtained information from investigators about adherence to practices that minimize the introduction of such bias in their clinical trials experience. METHODS: Email survey of clinical trial investigators from Canadian sites to learn about adherence to practices that help maintain research independence across all stages of trial preparation, conduct, and dissemination. The main outcome was the proportion of investigators that reported full adherence to preferred trial practices for all of their trials conducted from 2001-2006, stratified by funding source. RESULTS: 844 investigators responded (76%) and 732 (66%) provided useful information. Full adherence to preferred clinical trial practices was highest for institutional review of signed contracts and budgets (82% and 75% of investigators respectively). Lower rates of full adherence were reported for the other two practices in the trial preparation stage (avoidance of confidentiality clauses, 12%; trial registration after 2005, 39%). Lower rates of full adherence were reported for 7 practices in the trial conduct (35% to 43%) and dissemination (53% to 64%) stages, particularly in industry funded trials. 269 investigators personally experienced (n = 85) or witnessed (n = 236) a fCOI; over 70% of these situations related to industry trials. CONCLUSION: Full adherence to practices designed to promote the objectivity of research varied across trial stages and was low overall, particularly for industry funded trials. BioMed Central 2011-01-12 /pmc/articles/PMC3031202/ /pubmed/21226951 http://dx.doi.org/10.1186/1745-6215-12-9 Text en Copyright ©2011 Rochon et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Rochon, Paula A
Sekeres, Melanie
Hoey, John
Lexchin, Joel
Ferris, Lorraine E
Moher, David
Wu, Wei
Kalkar, Sunila R
Van Laethem, Marleen
Gruneir, Andrea
Gold, Jennifer
Maskalyk, James
Streiner, David L
Taback, Nathan
Chan, An-Wen
Investigator experiences with financial conflicts of interest in clinical trials
title Investigator experiences with financial conflicts of interest in clinical trials
title_full Investigator experiences with financial conflicts of interest in clinical trials
title_fullStr Investigator experiences with financial conflicts of interest in clinical trials
title_full_unstemmed Investigator experiences with financial conflicts of interest in clinical trials
title_short Investigator experiences with financial conflicts of interest in clinical trials
title_sort investigator experiences with financial conflicts of interest in clinical trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031202/
https://www.ncbi.nlm.nih.gov/pubmed/21226951
http://dx.doi.org/10.1186/1745-6215-12-9
work_keys_str_mv AT rochonpaulaa investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT sekeresmelanie investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT hoeyjohn investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT lexchinjoel investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT ferrislorrainee investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT moherdavid investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT wuwei investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT kalkarsunilar investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT vanlaethemmarleen investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT gruneirandrea investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT goldjennifer investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT maskalykjames investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT streinerdavidl investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT tabacknathan investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials
AT chananwen investigatorexperienceswithfinancialconflictsofinterestinclinicaltrials